08:33 AM EST, 01/14/2025 (MT Newswires) -- Firefly Neuroscience ( AIFF ) said Tuesday its BNA technology platform is able to assess a patient's biological brain age using cognitive data, potentially leading to a "scalable" approach to early screening for Alzheimer's patients.

The US Food and Drug Administration-approved platform used resting electroencephalography, or EEG, and cognitive EEG to assess the biological age of a person's brain, the company said.

Chief Technology Officer Gil Issachar said the technology "is capable of finding a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia."

Shares of the company soared more than 111% in Tuesday's premarket activity.